IL291465A - תכשירים ושיטות הקשורים למבני איזור קושר fc- אנטיגן מהונדסים הממוקדים ל- cd38 - Google Patents
תכשירים ושיטות הקשורים למבני איזור קושר fc- אנטיגן מהונדסים הממוקדים ל- cd38Info
- Publication number
- IL291465A IL291465A IL291465A IL29146522A IL291465A IL 291465 A IL291465 A IL 291465A IL 291465 A IL291465 A IL 291465A IL 29146522 A IL29146522 A IL 29146522A IL 291465 A IL291465 A IL 291465A
- Authority
- IL
- Israel
- Prior art keywords
- engineered
- compositions
- antigen binding
- binding domain
- methods related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902380P | 2019-09-18 | 2019-09-18 | |
| PCT/US2020/051663 WO2021055876A1 (en) | 2019-09-18 | 2020-09-18 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL291465A true IL291465A (he) | 2022-05-01 |
Family
ID=74884204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291465A IL291465A (he) | 2019-09-18 | 2022-03-17 | תכשירים ושיטות הקשורים למבני איזור קושר fc- אנטיגן מהונדסים הממוקדים ל- cd38 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4031166A1 (he) |
| JP (1) | JP2022548925A (he) |
| KR (1) | KR20220119362A (he) |
| CN (1) | CN114786713A (he) |
| AU (1) | AU2020351234A1 (he) |
| BR (1) | BR112022005036A2 (he) |
| CA (1) | CA3155187A1 (he) |
| IL (1) | IL291465A (he) |
| MX (1) | MX2022003316A (he) |
| WO (1) | WO2021055876A1 (he) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101472250B1 (ko) * | 2005-10-12 | 2014-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| SG195558A1 (en) * | 2008-10-14 | 2013-12-30 | Genentech Inc | Immunoglobulin variants and uses thereof |
| EP3505623A1 (en) * | 2014-02-14 | 2019-07-03 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| CA3049426A1 (en) * | 2017-01-06 | 2018-07-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
-
2020
- 2020-09-18 MX MX2022003316A patent/MX2022003316A/es unknown
- 2020-09-18 BR BR112022005036A patent/BR112022005036A2/pt not_active Application Discontinuation
- 2020-09-18 CA CA3155187A patent/CA3155187A1/en active Pending
- 2020-09-18 KR KR1020227012833A patent/KR20220119362A/ko unknown
- 2020-09-18 JP JP2022517471A patent/JP2022548925A/ja active Pending
- 2020-09-18 CN CN202080080169.6A patent/CN114786713A/zh active Pending
- 2020-09-18 EP EP20864518.4A patent/EP4031166A1/en not_active Withdrawn
- 2020-09-18 WO PCT/US2020/051663 patent/WO2021055876A1/en unknown
- 2020-09-18 AU AU2020351234A patent/AU2020351234A1/en not_active Abandoned
-
2022
- 2022-03-17 IL IL291465A patent/IL291465A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020351234A1 (en) | 2022-04-28 |
| MX2022003316A (es) | 2022-07-11 |
| BR112022005036A2 (pt) | 2022-07-05 |
| EP4031166A1 (en) | 2022-07-27 |
| WO2021055876A1 (en) | 2021-03-25 |
| JP2022548925A (ja) | 2022-11-22 |
| KR20220119362A (ko) | 2022-08-29 |
| CA3155187A1 (en) | 2021-03-25 |
| CN114786713A (zh) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280046A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc הממוקדים ל cd38 | |
| EP3565595A4 (en) | COMPOSITIONS AND METHODS ASSOCIATED WITH DOMAIN CONSTRUCTIONS OF BINDING TO MANIPULATED FC ANTIGEN | |
| IL263213A (he) | תכשירים ושיטות הקשורים למבני fc מהונדסים | |
| IL273875A (he) | שיטות ותרכובות עבור עיכוב ביטוי של ldha | |
| IL280044A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc | |
| IL268815A (he) | תכשירים ושיטות לטרנסדוקצית שאת | |
| SG10202107391YA (en) | Compositions and methods related to engineered fc constructs | |
| IL278701A (he) | תרכובות פירידונים הטרו-דחוסות והשימוש בהן כמעכבי idh | |
| IL291509A (he) | אפנון תכשירי מיקרוביוטה באמצעות נוקליאזים מיועדים | |
| IL279998A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc | |
| IL280014A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc הממוקדים ל ctla-4 | |
| EP3737384C0 (en) | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING CONDITIONS ASSOCIATED WITH ALPHA-SYNUCLEIN | |
| IL279999A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc | |
| IL279989A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc | |
| IL280038A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc הממוקדים ל pd-l1 | |
| IL279987A (he) | תכשירים ושיטות הקשורים למבנים מהונדסים עם אתר קושר אנטיגן-fc הממוקדים ל-ccr4 | |
| IL291465A (he) | תכשירים ושיטות הקשורים למבני איזור קושר fc- אנטיגן מהונדסים הממוקדים ל- cd38 | |
| IL290219A (he) | תרכובות ושיטות לקשירת נוגדנים ועיכוב נוגדנים מנטרלים | |
| ZA202007107B (en) | Compositions comprising pcsk9-binding molecules and methods of use | |
| ZA202002763B (en) | Fuel additive compositions, and method of use thereof | |
| PL3577266T3 (pl) | Ulepszone kompozycje środków wiążących i ich zastosowania | |
| IL284350A (he) | תכשירי דומפרידון ושיטות לטיפול בדיכאון |